


Comparison: 8-year outcomes of RESILIA tissue valves vs. Non-RESILIA tissue valves



*Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.

Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. *J Thorac Cardiovasc Surg.* 2024 Sep;168(3):781-791



Edwards

In an 8-year, propensity-matched comparison between RESILIA tissue valves and non-RESILIA tissue valves, RESILIA tissue valves performed significantly better in:

Freedom from

SVD

Freedom from

**reoperation
due to SVD**

Freedom from

**all-cause
reoperation**

The study represents the longest follow-up and first long-term propensity-matched analysis comparing outcomes from the novel calcification-resistant RESILIA tissue treatment versus a widely used contemporary bioprosthesis.



Study comparison

- ✓ Multicenter
- ✓ Single-arm
- ✓ Clinical events committee
- ✓ SVD Definition: Akins et al. (2008)



RESILIA

Tissue at 8 years[†]

Size

689

patients

(239 reconsented)

Mean age

66.9

years old



Non-RESILIA

Tissue at 8 years[‡]

Size

258

patients

Mean age

68.5

years old




[†]The RESILIA tissue valve cohort consisted of patients from the COMMENCE aortic trial (n=689)

[‡]The non-RESILIA tissue valve cohort originated from the Carpentier-Edwards PERIMOUNT Magna Ease post approval study (n=258)

RESILIA tissue valves demonstrated significantly improved freedom from SVD, reoperation due to SVD, and reoperation compared to the non-RESILIA tissue valves

Outcomes at 8 years (Kaplan-Meier analyses)


RESILIA tissue valves Non-RESILIA tissue valves




Note: Superiority Test Log-Rank P-Value

RESILIA tissue valves demonstrated clinically stable hemodynamics through 8 years


Mean Gradient (mmHg)




EOA (cm²)



RESILIA tissue valves delivered a favorable safety profile through 8 years**



This study supports the choice of RESILIA tissue valves over non-RESILIA tissue valves for SAVR in patients aiming to maximize life expectancy while minimizing cumulative risk



Interested in learning more?
Scan for the clinical summary

A grey rectangular box contains a circular QR code on the left and a circular icon of a document with lines on the right. Below the QR code and icon, the text 'Interested in learning more? Scan for the clinical summary' is written in a black sans-serif font.

**Data from Kaplan Meier analysis after Propensity Score Adjustment

The INSPIRIS RESILIA aortic valve with RESILIA tissue technology

Leads the world as the most implanted surgical aortic tissue valve.

The INSPIRIS RESILIA valve incorporates novel VFit technology, designed to enable valve-in-valve procedures in the future, at a time when patients are older and potentially at a higher risk for complications.

Built on the Carpentier-Edwards PERIMOUNT valve platform, which is backed by over 40 years of real-world experience.



Explore the benefits at
[Edwards.com/INSPIRIS](https://www.edwards.com/INSPIRIS)

1. Kaneko, T, Johnston D, Bavaria JE, et al. Propensity-matched 8-year Outcomes Following Surgical Aortic Valve Replacement With Novel Calcificationresistant Versus Contemporary Tissue Bioprostheses. Presented at the Heart Valve Society Annual Scientific Meeting, April 2025.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Refer to device instructions for use for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures. VFit technology is available on sizes 19–25 mm.

Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, Carpentier-Edwards, Carpentier-Edwards PERIMOUNT, INSPIRIS, INSPIRIS RESILIA, RESILIA and VFit are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2025 Edwards Lifesciences Corporation . All rights reserved. PP--EU-10367 v1.0

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](https://www.edwards.com)



Edwards